Evidence map›Paper›PMID 39367742›Full record

ArticleMovement disorders clinical practice2024

Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease.

Yiwen Shi, Roseanne Dobkin, Daniel Weintraub, Hyunkeun R Cho, Chelsea Caspell-Garcia, Meredith Bock, Ethan Brown, Dag Aarsland, Nabila Dahodwala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Redefining Non-Motor Symptoms in Parkinson's Disease.Journal of personalized medicine · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yiwen ShiDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0009-0007-7193-1928
Roseanne DobkinDepartment of Psychiatry, Rutgers University, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Daniel WeintraubDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0633-7168
Hyunkeun R ChoDepartment of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
Chelsea Caspell-GarciaDepartment of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
Meredith BockDepartment of Neurology, The San Francisco Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-8704-916X
Ethan BrownDepartment of Neurology, The San Francisco Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9744-8562
Dag AarslandDepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Nabila DahodwalaDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnxiety and depression are common non-motor symptoms in Parkinson's disease (PD) but remain under-recognized and under-treated.

objectivesTo evaluate functional outcomes associated with baseline anxiety or depression and effects related to the initiation of new psychiatric treatment.

methodsWe analyzed 7 years of data from patients with de novo PD enrolled in the Parkinson's Progression Markers Initiative. Longitudinal regression models evaluated the association between baseline anxiety and depression with Schwab and England (SE) and MDS-UPDRS total scores over time. Cox proportional hazard models assessed effects of baseline anxiety and depression on time to initiation of dopaminergic therapy. Piecewise linear regression models examined the association of treatment initiation for anxiety and depression with SE and MDS-UPDRS.

results490 participants with baseline depression and anxiety data were included. Anxiety and depression were associated with lower SE (anxiety: β = -1.31, P = 0.038, depression: β = -1.96, P = 0.012, co-morbid: β = -2.70, P = 0.003) and higher MDS-UPDRS scores (anxiety: β = 5.37, P < 0.001, depression: β = 9.17, P < 0.001, co-morbid: β = 10.50, P < 0.001) longitudinally. Anxiety was associated with faster time to dopamine replacement therapy initiation (HR 1.30, 95% CI 1.03-1.66, P = 0.03). 16 participants with anxiety initiated treatment for anxiety, which was associated with subsequent lower levodopa daily dose (slope change = -218.49, P = 0.018). 10 participants with depression initiated treatment of depression, which was associated with reduced MDS-UPDRS total scores (slope change = -8.3, P < 0.001) and higher SE scores (slope change = 5.99, P = 0.004).

conclusionsAnxiety and depression at PD onset are associated with multiple negative longitudinal trajectories. However, preliminary findings suggest that anxiety and depression treatment may be linked with improved motor and non-motor outcomes.

Indexed as

AnxietyDepressionParkinson DiseaseAgedDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedSeverity of Illness IndexTreatment Outcomeanxiety and depressionneuropsychiatric symptomsParkinson's diseasePPMI

Identifiers

PMID39367742
PMCPMC11452785

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.